XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.25.1

Royalty and Commercial Payment Purchase Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Royalty and Commercial Payment Purchase Agreements |
Summary of royalty and commercial payment receivable and contingent consideration activities | The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the three months ended March 31, 2025 (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Acquisition of Royalty | ​ | ​ | Receipt of Royalty | ​ | ​ | ​
​ | ​ | ​ | Balance as of | ​ | ​ | and Commercial | ​ | ​ | and Commercial | ​ | ​ | Balance as of
​ | ​ | ​ | January 1, 2025 | ​ | ​ | Payment Receivables | ​ | ​ | Payments | ​ | ​ | March 31, 2025
Twist | ​ | $ | 15,000 | ​ | $ | — | ​ | $ | — | ​ | $ | 15,000
Daré (XACIATO) | ​ | ​ | 21,999 | ​ | ​ | — | ​ | ​ | (2) | ​ | ​ | 21,997
LadRx (MIPLYFFA) | ​ | ​ | 4,850 | ​ | ​ | — | ​ | ​ | (413) | ​ | ​ | 4,437
Palobiofarma | ​ | ​ | 10,000 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,000
Kuros | ​ | ​ | 4,500 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,500
Castle Creek | ​ | ​ | — | ​ | ​ | 4,395 | ​ | ​ | — | ​ | ​ | 4,395
Total | ​ | $ | 56,349 | ​ | $ | 4,395 | ​ | $ | (415) | ​ | $ | 60,329
​ The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the three months ended March 31, 2025 (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Income from | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Purchased | ​ | Receipt of | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Receivables | ​ | Royalty and | ​ | Payment of | ​ | ​
​ | ​ | Balance as of | ​ | Under the | ​ | Commercial | ​ | Sales-Based | ​ | Balance as of
​ | ​ | January 1, 2025 | ​ | EIR Method | ​ | Payments | ​ | Milestone | ​ | March 31, 2025
Affitech (VABYSMO) | ​ | $ | 13,105 | ​ | $ | 5,817 | ​ | $ | (11,145) | ​ | $ | 3,000 | $ | 10,777
Aptevo (IXINITY) | ​ | ​ | 6,628 | ​ | ​ | 253 | ​ | ​ | (561) | ​ | ​ | — | ​ | 6,320
Total | ​ | $ | 19,733 | ​ | $ | 6,070 | ​ | $ | (11,706) | ​ | $ | 3,000 | $ | 17,097
Summary of income from purchased receivables under the cost recovery method and EIR method | The following table summarizes income from purchased receivables under the cost recovery method and EIR method during the three months ended March 31, 2025 (in thousands):
​ | ​ | ​ | ​
​ | ​ | ​ | Three months ended March 31, 2025
Viracta (OJEMDA) | ​ | ​ | 5,525
Total income from purchased receivables under the cost recovery method | ​ | $ | 5,525
​ | ​ | ​ | ​
Affitech (VABYSMO) | ​ | ​ | 5,817
Aptevo (IXINITY) | ​ | ​ | 253
Total income from purchased receivables under the EIR method | ​ | $ | 6,070
​

X
- References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of income from from purchased receivables under the cost recovery method and EIR method. + References No definition available. + Details
Name: | xoma_ScheduleOfIncomeFromPurchasedReceivablesTableTextBlock
Namespace Prefix: | xoma_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in royalty and commercial payment receivables, including contingent consideration under RPAs, AAAs, and CPPAs activities. + References No definition available. + Details
Name: | xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock
Namespace Prefix: | xoma_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration